The Fast and the Urticarious

Chronic Spontaneous Urticaria (CSU) management requires selecting between remibrutinib, omalizumab, and dupilumab. Dr. Jason Hawkes advocates for remibrutinib as a first-line therapy, emphasizing its rapid onset of action and direct mechanism targeting mast cell degranulation, which effectively addresses both IgE-dependent and IgE-independent disease subtypes. Conversely, the panel highlights omalizumab’s established safety profile, extensive clinical track record, and favorable insurance accessibility as compelling reasons for its continued use. While remibrutinib offers faster symptom relief—a critical factor for patients suffering from sleep disruption and severe angioedema—omalizumab remains a reliable, long-term standard. Ultimately, the choice between these agents involves balancing the immediate, high-speed efficacy of oral remibrutinib against the proven, sustained control provided by established injectable biologics, necessitating a shared decision-making process that prioritizes patient-specific needs and the urgency of symptom relief.